Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Biphenotypic, Acute 1

Interventions

Rituximab 67Cyclophosphamide 39Vincristine 33Prednisone 31Doxorubicin 25Lenalidomide 18Radiotherapy 16Bendamustine Hydrochloride 14Peripheral Blood Stem Cell Transplantation 10Filgrastim 10Etoposide 10Prednisolone 8tofacitinib 7obinutuzumab 6ibritumomab tiuxetan 6fludarabine 6VAP-cyclo protocol 6Mitoxantrone 6Methylprednisolone 6Deoxycholic Acid 6Cytarabine 6Melphalan 5Dexamethasone 5Carmustine 5ibrutinib 4fludarabine phosphate 4R-CHOP protocol 4Methotrexate 4Interferon-alpha 4Idarubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Follicular × Inotuzumab Ozogamicin × Clear all
NCT00562965 2018-01-09

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Pfizer

Phase 3 Terminated
29 enrolled 14 charts
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡